Boehringer Ingelheim has exercised the option under its Pharmaxis alliance to acquire the investigational drug PXS4728A for the treatment of the liver-related condition NASH. PXS4728A is a Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor that works as an anti-inflammatory, and in Phase I studies, demonstrated oral bioavailability, long-lasting target inhibition and good safety and tolerability.     Pharmaxis will receive $39 million upfront and is eligible...